SELLAS Life Sciences Group, Inc. — Director's Dealing 2015

Dec 23, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2015-12-18

Reporting Person: SCHWARTZ MARK W. (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-18	Stock Option (right to buy)	$1.5	A	1250000	Acquired	2025-12-18	Common Stock (1250000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.

F2: The stock option will vest in 16 equal, quarterly installments over 4 years, beginning 3 months from the date of grant, so long as the Reporting Person remains in the company's continuous employ of the Issuer through the vesting period.